Advagene Biopharma Co. Ltd. (6709.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan
Advagene Biopharma Co. Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -70.82 m TWD | -70.92 m TWD |
| EBIT | -69.27 m TWD | -68.11 m TWD |
| Net income | -69.42 m TWD | -68.29 m TWD |
| Diluted EPS – continuing operations | -1.16 TWD | -1.14 TWD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.
More stocks
- Rein Therapeutics, Inc. (RNTX)
- LumenRadio AB (LUMEN.ST)
- Atlas Lithium Corp (ATLX)
- De Poan Pneumatic (1570.TWO)
- Charlotte's Web Holdings, Inc. (CWBHF)
- EgnsINVEST Ejendomme Tyskland A/S (EGNETY.CO)
- Empresas la Polar SA (ABC.SN)
- DLH Holdings Corp. (DLHC)
- CombinedX AB (CX.ST)
- Bangkok Ranch PCL (BR.BK)
- Dong In Entech Co., Ltd (111380.KS)
- Sibek AB (publ) (SIBEK.ST)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.